AstraZeneca and Daiichi Sankyo Withdraw EU Application for Lung Cancer Drug Datopotamab Deruxtecan Due to Non-Significant Survival Improvement

Dec 24, 2024, 11:37 AM

AstraZeneca, in collaboration with Daiichi Sankyo, has voluntarily withdrawn its marketing authorization application for the lung cancer drug datopotamab deruxtecan ($Dato-DXd) from the European Union's medicines regulator. The decision follows feedback from the European Medicines Agency after trial results from the phase advanced study TROPION-Lung01 showed that the drug did not significantly improve patient survival rates. The drug, also known as Dato-DXd, had previously received the designation of innovative therapy from the U.S. Food and Drug Administration earlier this month for its results in treating a specific type of lung cancer. Dato-DXd belongs to a promising group of treatments known as antibody-drug conjugates.